放射性粒子植入治疗前列腺癌的研究进展

郝颖; 张青; 郭宏骞

doi:10.13201/j.issn.1001-1420.2024.02.016

放射性粒子植入治疗前列腺癌的研究进展

- 1.
  江苏大学鼓楼临床医学院泌尿外科(南京，210000)
- 2.
  南京鼓楼医院泌尿外科
基金项目:
中德合作交流项目(No：M-0670)

详细信息

通讯作者: 郭宏骞，E-mail：dr.ghq@nju.edu.cn

中图分类号: R737.25

收稿日期: 2023-05-13

刊出日期: 2024-02-06

Research progress of radioactive particle implantation in treatment of prostate cancer

- 1.
  Department of Urology, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210000, China
- 2.
  Department of Urology, Nanjing Drum Tower Hospital

More Information

Corresponding author: GUO Hongqian, E-mail: dr.ghq@nju.edu.cn

Received Date: 13 May 2023

Publish Date: 06 February 2024

摘要

摘要: 前列腺癌(prostate cancer，PCa)是发生在前列腺的上皮性恶性肿瘤，是男性泌尿生殖系统常见的恶性肿瘤。粒子植入全称为“放射性粒子植入治疗技术”，是一种将¹²⁵I或¹⁰³Pd等含放射性的粒子按计划植入肿瘤内部以摧毁肿瘤的治疗手段。现代前列腺粒子植入治疗是一种经会阴、经直肠超声引导的技术，具有微创、损伤小、术后恢复快、最大程度地保留前列腺功能及尿道功能等优势。本文将从粒子植入的定位手段、单一治疗和联合治疗的疗效、并发症及其他相关研究等方面探讨粒子植入治疗的潜力、患者选择及未来的发展方向。
- 前列腺癌 /
- 近距离放射治疗 /
- 粒子植入
Abstract: Prostate cancer (PCa) is an epithelial malignant tumor that occurs in the prostate, and is a common malignant tumor of the male genitourinary system. Particle implantation, which stands for "radioactive particle implantation therapy technology" is a treatment that implants radioactive particles such as ¹²⁵I or ¹⁰³Pd into the tumor as planned to destroy the tumor. Modern prostate particle implantation is a technique under the guidance of transperineal and transrectal ultrasound, which has the advantages of minimal invasion, small injury, quick postoperative recovery, and maximum preservation of the functions of prostate and urethral. This article will discuss the potential of particle implantation, patient selection and future development direction from the aspects of positioning means of particle implantation, efficacy of single therapy and combination therapy, complications and other related studies.
- prostate cancer /
- brachytherapy /
- particle implantation

HTML全文

参考文献(50)

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	杨勇. 耻骨后¹²⁵I永久植入治疗局限性前列腺癌的长期随访结果[J]. 中华泌尿外科杂志, 1997, 18(11): 701.
[3]	聂影坤, 申亦宁. 经会阴植入¹²⁵I粒子近距离治疗局限性前列腺癌[J]. 国外医学(临床放射学分册), 2001, 24(3): 191.
[4]	Henry A, Pieters BR, Siebert FA, et al. GEC-ESTRO ACROP prostate brachytherapy guidelines[J]. Radiother Oncol, 2022, 167: 244-251. doi: 10.1016/j.radonc.2021.12.047
[5]	Nosrati R, Wronski M, Tseng CL, et al. Postimplant dosimetry of permanent prostate brachytherapy: comparison of MRI-only and CT-MRI fusion-based workflows[J]. Int J Radiat Oncol Biol Phys, 2020, 106(1): 206-215. doi: 10.1016/j.ijrobp.2019.10.009
[6]	Grajales D, Kadoury S, Shams R, et al. Performance of an integrated multimodality image guidance and dose-planning system supporting tumor-targeted HDR brachytherapy for prostate cancer[J]. Radiother Oncol, 2022, 166: 154-161. doi: 10.1016/j.radonc.2021.11.026
[7]	Nosrati R, Soliman A, Safigholi H, et al. MRI-based automated detection of implanted low dose rate(LDR)brachytherapy seeds using quantitative susceptibility mapping(QSM)and unsupervised machine learning(ML)[J]. Radiother Oncol, 2018, 129(3): 540-547. doi: 10.1016/j.radonc.2018.09.003
[8]	Viktorin-Baier P, Putora PM, Schmid HP, et al. Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry[J]. BJU Int, 2020, 125(6): 827-835. doi: 10.1111/bju.15003
[9]	Uribe-Lewis S, Uribe J, Bourke V, et al. Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience[J]. BJU Int, 2022, 129(6): 723-730. doi: 10.1111/bju.15585
[10]	Tharmalingam H, Tsang Y, Ostler P, et al. Single dose high-dose rate(HDR)brachytherapy(BT)as monotherapy for localised prostate cancer: early results of a UK national cohort study[J]. Radiother Oncol, 2020, 143: 95-100. doi: 10.1016/j.radonc.2019.12.017
[11]	Corkum M, Loblaw A, Hasan Y, et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase Ⅱ clinical trial[J]. Radiother Oncol, 2021, 156: 160-165. doi: 10.1016/j.radonc.2020.12.021
[12]	Alayed Y, Loblaw A, McGuffin M, et al. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost[J]. Radiother Oncol, 2021, 154: 29-35. doi: 10.1016/j.radonc.2020.09.007
[13]	Siddiqui ZA, Gustafson GS, Ye H, et al. Five-year outcomes of a single-institution prospective trial of 19-gy single-fraction high-dose-rate brachytherapy for low-and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 104(5): 1038-1044. doi: 10.1016/j.ijrobp.2019.02.010
[14]	Yamazaki H, Masui K, Suzuki G, et al. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer[J]. Radiother Oncol, 2019, 132: 162-170. doi: 10.1016/j.radonc.2018.10.020
[15]	Smith WH, Cesaretti J, Chin CP, et al. Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy[J]. Radiother Oncol, 2021, 155: 42-47. doi: 10.1016/j.radonc.2020.10.021
[16]	辛宇鹏, 郭道宁, 邵红刚, 等. ¹²⁵I粒子植入治疗前列腺癌的临床研究[J]. 解放军医药杂志, 2018, 30(11): 40-43. doi: 10.3969/j.issn.2095-140X.2018.11.010
[17]	Parry MG, Nossiter J, Sujenthiran A, et al. Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study[J]. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1219-1229. doi: 10.1016/j.ijrobp.2020.11.023
[18]	Gogineni E, Rana Z, Soberman D, et al. Biochemical control and toxicity outcomes of stereotactic body radiation therapy versus low-dose-rate brachytherapy in the treatment of low-and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1232-1242. doi: 10.1016/j.ijrobp.2020.11.003
[19]	Sanmamed N, Lee J, Berlin A, et al. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy(HDR)or integrated VMAT(IB-VMAT)boost: Dosimetry, toxicity and health related quality of life[J]. Radiother Oncol, 2020, 149: 240-245. doi: 10.1016/j.radonc.2020.05.029
[20]	张建, 李春生, 高琳, 等. ¹²⁵I放射性粒子植入联合间歇性内分泌治疗对前列腺癌的临床疗效[J]. 中国医师杂志, 2021, 23(1): 77-80. doi: 10.3760/cma.j.cn431274-20191210-01413
[21]	崔嵛, 陈惠庆, 宋继文, 等. ¹²⁵I粒子植入联合内分泌治疗对中高危高龄前列腺癌患者的治疗效果分析[J]. 中国药物与临床, 2018, 18(12): 2147-2148.
[22]	罗鹏伟, 王亮, 曹文锋, 等. ¹²⁵I粒子植入联合最大限度雄激素阻断治疗转移性前列腺癌的临床远期随访研究[J]. 中华男科学杂志, 2019, 25(1): 29-34.
[23]	Pickles T, Tyldesley S, Hamm J, et al. Brachytherapy for intermediate-risk prostate cancer, androgen deprivation, and the risk of death[J]. Int J Radiat Oncol Biol Phys, 2018, 100(1): 45-52. doi: 10.1016/j.ijrobp.2017.08.042
[24]	Hoskin PJ, Rojas AM, Ostler PJ, et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results[J]. Radiother Oncol, 2021, 154: 214-219. doi: 10.1016/j.radonc.2020.09.047
[25]	Lee DJ, Barocas DA, Zhao ZG, et al. Comparison of patient-reported outcomes after external beam radiation therapy and combined external beam with low-dose-rate brachytherapy boost in men with localized prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 102(1): 116-126. doi: 10.1016/j.ijrobp.2018.05.043
[26]	Kollmeier MA, McBride S, Varghese M, et al. Low-dose-rate brachytherapy combined with ultrahypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: results from a prospective trial[J]. Int J Radiat Oncol Biol Phys, 2020, 108(4): 905-913. doi: 10.1016/j.ijrobp.2020.05.032
[27]	Wedde TB, Smästuen MC, Brabrand S, et al. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort[J]. Radiother Oncol, 2019, 132: 211-217. doi: 10.1016/j.radonc.2018.10.013
[28]	陈波, 周荣升, 郝林, 等. I125放射粒子永久性植入联合外放射治疗前列腺癌骨转移的疗效研究[J]. 中华转移性肿瘤杂志, 2018, 1(3): 21-25.
[29]	Wang H, Mendez LC, Morton G, et al. Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: an exploratory study[J]. Radiother Oncol, 2021, 155: 80-85. doi: 10.1016/j.radonc.2020.10.029
[30]	王增增, 徐勇. ¹²⁵I粒子植入放疗对前列腺癌免疫微环境影响的初步分析[J]. 临床泌尿外科杂志, 2022, 37(4): 261-267. https://lcmw.whuhzzs.com/article/doi/10.13201/j.issn.1001-1420.2022.04.004
[31]	Yuan ZG, Fernandez D, Dhillon J, et al. Proof-of-principle Phase Ⅰ results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis[J]. Prostate Cancer Prostatic Dis, 2021, 24(1): 140-149. doi: 10.1038/s41391-020-0254-y
[32]	毕缓, 曾宇, 付水, 等. 人参皂苷Rg3联合¹²⁵I粒子植入对中晚期前列腺癌的疗效及对患者血清TGF和VEGF的影响[J]. 疑难病杂志, 2019, 18(3): 280-284. doi: 10.3969/j.issn.1671-6450.2019.03.015
[33]	徐礼臻, 叶肖, 朱再生, 等. 复方玄驹胶囊用于前列腺癌¹²⁵I粒子植入术后阳痿的疗效分析[J]. 中国性科学, 2017, 26(1): 8-10. doi: 10.3969/j.issn.1672-1993.2017.01.002
[34]	王欢, 赵颖, 谷爱丽, 等. 高频热疗对前列腺癌碘125粒子植入后尿路合并症的疗效观察[J]. 中国煤炭工业医学杂志, 2021, 24(5): 514-518.
[35]	曾萧贤, 张国旭, 张文文. ¹²⁵I粒子联合锝99-二甲基二磷酸盐治疗前列腺癌骨转移的近期临床研究[J]. 中国临床实用医学, 2019, 10(5): 20-24. doi: 10.3760/cma.j.issn.1673-8799.2019.05.006
[36]	张春霆, 朱再生, 罗荣利, 等. 前列腺癌粒子植入后性功能状况及危险因素分析[J]. 中国性科学, 2017, 26(8): 5-7.
[37]	Stone NN, Winoker JS, Kaplan SA, et al. Factors influencing long-term urinary symptoms after prostate brachytherapy[J]. BJU Int, 2018, 122(5): 831-836. doi: 10.1111/bju.14365
[38]	赵佳晖, 侯铸, 罗勇, 等. ¹²⁵Ⅰ粒子植入术治疗前列腺癌尿路并发症的临床分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(5): 400-403. doi: 10.3877/cma.j.issn.1674-3253.2022.05.004
[39]	Mazzone E, Mistretta FA, Knipper S, et al. Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis[J]. BJU Int, 2019, 124(6): 1006-1013. doi: 10.1111/bju.14841
[40]	Vigneault E, Martell K, Taussky D, et al. Does seed migration increase the risk of second malignancies in prostate cancer patients treated with iodine-125 loose seeds brachytherapy?[J]. Int J Radiat Oncol Biol Phys, 2018, 100(5): 1190-1194. doi: 10.1016/j.ijrobp.2017.12.273
[41]	张为玺, 张永德, 王彬, 等. 3P悬臂式前列腺癌粒子植入机器人结构设计与仿真[J]. 北京工业大学学报, 2022, 48(1): 8-15.
[42]	Rajković KM, Dabić-Stanković K, Stanković J, et al. Modelling and optimisation of treatment parameters in high-dose-rate mono brachytherapy for localised prostate carcinoma using a multilayer artificial neural network and a genetic algorithm: pilot study[J]. Comput Biol Med, 2020, 126: 104045. doi: 10.1016/j.compbiomed.2020.104045
[43]	Jørgensen EB, Buus S, Bentzen L, et al. 3D dose reconstruction based on in vivo dosimetry for determining the dosimetric impact of geometric variations in high-dose-rate prostate brachytherapy[J]. Radiother Oncol, 2022, 171: 62-68. doi: 10.1016/j.radonc.2022.01.006
[44]	Mountris KA, Visvikis D, Bert J. DVH-based inverse planning using Monte Carlo dosimetry for LDR prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2019, 103(2): 503-510. doi: 10.1016/j.ijrobp.2018.09.041
[45]	Poder J, Howie A, Brown R, et al. Towards real time in-vivo rectal dosimetry during trans-rectal ultrasound based high dose rate prostate brachytherapy using MOSkin dosimeters[J]. Radiother Oncol, 2020, 151: 273-279. doi: 10.1016/j.radonc.2020.08.003
[46]	Hagan CT, Bloomquist C, Kim I, et al. Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment[J]. Acta Biomater, 2022, 148: 163-170. doi: 10.1016/j.actbio.2022.06.023
[47]	Teyateeti A, Grossman C, Kollmeier MA, et al. Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity[J]. BJU Int, 2022, 129(3): 337-344. doi: 10.1111/bju.15572
[48]	倪红霞, 费锋燕. 纽曼式护理干预在内分泌联合¹²⁵Ⅰ粒子植入治疗局限性晚期前列腺癌患者中的应用[J]. 护理实践与研究, 2019, 16(9): 82-84. doi: 10.3969/j.issn.1672-9676.2019.09.035
[49]	孙建民, 黄晓云, 张舒翔. ¹²⁵I粒子植入治疗前列腺癌术中及术后医护人员受照水平评估[J]. 中国冶金工业医学杂志, 2021, 38(6): 708-709.
[50]	杨剑, 耿建华, 洪浩, 等. ¹²⁵I粒子植入治疗的前列腺癌患者出院后对周围人员辐射水平的研究[J]. 中国医学装备, 2018, 15(4): 23-27. doi: 10.3969/J.ISSN.1672-8270.2018.04.006